(1S,3R)-3-acetoxy-1-cyclohexanol | 888024-96-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S,3R)-3-acetoxy-1-cyclohexanol
• 英文别名: (1R,3S)-3-hydroxycyclohexyl acetate；[(1R,3S)-3-hydroxycyclohexyl] acetate
• CAS: 888024-96-2
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: KKGVEAWZDIBQMT-JGVFFNPUSA-N

物化性质

• 沸点：
  224.9±23.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,3R)-3-acetoxy-1-cyclohexanol 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 以20%的产率得到(1R,3R)-3-(3-(4-phenoxyphenyl)-4-((triphenyl-5-phosphinidene)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl acetate
  参考文献：
  名称：

  EP3912980

  摘要：

  公开号：
• 作为产物：
  描述：

  1,3-环己二醇 在 乙酸-4-氯苯酯 吡啶 、 Pseudomonas cepacia lipase 、 [Ru₂(CO)4(C₅Ph₄OH)2] 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 76.0h， 生成 (1S,3R)-3-acetoxy-1-cyclohexanol
  参考文献：
  名称：

  Enzymatic Resolution, Desymmetrization, and Dynamic Kinetic Asymmetric Transformation of 1,3-Cycloalkanediols

  摘要：

  An efficient desymmetrization of cis-1,3-cyclohexanediol to (1S, 3R)-3-(acetoxy)-1-cyclohexanol ((R, S)-2a) was performed via Candida antarctica lipase B (CALB)-catalyzed transesterification, in high yield (up to 93%) and excellent enantioselectivity (ee's up to > 99.5%). (R, R)-Diacetate ((R, R)-3a) was obtained in a DYKAT process at room temperature from (1S, 3R)-3-acetoxy-1-cyclohexanol ((R, S)-2a), in a high trans/cis ratio (91: 9) and in excellent enantioselectivity of > 99%. Metal- and enzyme-catalyzed dynamic transformation of cis/trans-1,3-cyclohexanediol using PS-C gave a high diastereoselectivity for cis-diacetate (cis/trans) 97: 3). The (1R, 3S)-3-acetoxy-1-cyclohexanol (ent-(R, S)-2a) was obtained from cis-diacetate by CALB-catalyzed hydrolysis in an excellent yield (97%) and selectivity (> 99% ee). By deuterium labeling it was shown that intramolecular acyl migration does not occur in the transformation of cis-monoacetate to the cis-diacetate.

  DOI：

  10.1021/jo060002n

文献信息

• METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES
  申请人：Salagnad Christophe

  公开号：US20070197614A1

  公开（公告）日：2007-08-23

  The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.

  本发明涉及一种制备公式（I）的二芳基环烷基衍生物的方法，其中各自的R基取代基如本文所定义。公式（I）化合物是过氧化物酶体增殖物激活受体（PPAR激活剂），在治疗多发性硬化症、帕金森病、精神障碍等中枢神经系统疾病和疾病方面非常有用。本发明提供了一种新的制备公式（I）的PPAR激活剂的方法，该方法不具有先前技术中已知的缺点。特别是，提供了一种方法，可以在不需要后续手性色谱的情况下以适当的对映选择性制备公式（I）的PPAR激活剂，即高对映选择性。
• NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES
  申请人：Salagnad Christophe

  公开号：US20080051583A1

  公开（公告）日：2008-02-28

  The invention relates generally to intermediate compounds derived during the process for preparing diarylcycloalkyl derivatives which are activators for peroxisome proliferator-activated receptors (PPAR activators) and are therefore useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The intermediate compounds of the present invention are defined structurally by the formulae (Ia): and formula (II): wherein the respective substituent groups are defined herein.

  本发明涉及制备二苯基环烷衍生物的过程中产生的中间化合物，该化合物是过氧化物酶体增殖物活化受体（PPAR活化剂），因此在治疗多发性硬化症、帕金森病、精神障碍等中枢神经系统疾病和疾病方面具有用处。本发明的中间化合物在结构上由公式（Ia）和公式（II）定义，其中各取代基在此定义。
• CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR
  申请人：Minghui Pharmaceutical (Shanghai) Limited

  公开号：EP3912980A1

  公开（公告）日：2021-11-24

  The present invention relates to a novel molecule with protein tyrosine kinase inhibitory activity, and the synthesis and usage thereof. Specifically, the present invention relates to compound by formula A, pharmaceutically acceptable salts, hydrates or solvates thereof, and the synthesis and usage thereof.

  本发明涉及一种具有蛋白酪氨酸激酶抑制活性的新型分子及其合成和使用方法。具体地说，本发明涉及式 A 的化合物、其药学上可接受的盐、水合物或溶液及其合成和使用方法。
• [EN] CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR<br/>[FR] MOLÉCULES CYCLIQUES SERVANT D'INHIBITEUR DE LA TYROSINE KINASE DE BRUTON<br/>[ZH] 作为布鲁顿酪氨酸激酶抑制剂的环状分子
  申请人：MINGHUI PHARMACEUTICAL SHANGHAI LTD

  公开号：WO2020147798A1

  公开（公告）日：2020-07-23

  本发明描述了具有蛋白酪氨酸激酶抑制活性的新型分子，以及该化合物的合成和使用方法。具体地，本发明描述了式（A）化合物或其药学上可接受的盐、水合物或溶剂合物，以及该化合物的合成和使用方法。
• Fleming, Ian; Henning, Rolf; Parker, David C., Journal of the Chemical Society. Perkin transactions I, 1995, # 4, p. 317 - 338
  作者：Fleming, Ian、Henning, Rolf、Parker, David C.、Plaut, Howard E.、Sanderson, Philip E. J.

  DOI：——

  日期：——